Epidemiology of benign prostatic hyperplasia

被引:25
|
作者
Robert, G. [1 ]
De La Taille, A. [2 ]
Descazeaud, A. [3 ]
机构
[1] CHU Bordeaux, Serv Urol, Bordeaux, France
[2] CHU Henri Mondor, AP HP, Serv Urol, Creteil, France
[3] CHU Limoges, Serv Urol, F-87042 Limoges, France
来源
PROGRES EN UROLOGIE | 2018年 / 28卷 / 15期
关键词
Benign prostatic hyperplasia; Epidemiology; Prevalence; Incidence; URINARY-TRACT SYMPTOMS; CLINICAL PROGRESSION; NATURAL-HISTORY; RISK-FACTORS; MEN; POPULATION; DUTASTERIDE; DYSFUNCTION; PREVALENCE; RETENTION;
D O I
10.1016/j.purol.2018.08.005
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Introduction. - Epidemiological data concerning benign prostatic hyperplasia are numerous but highly variable depending on the definition of the pathology that is selected and on the source of information used. The objective of this work was to present an inventory of the main epidemiological data available in France and worldwide. Material and method. - A literature review was conducted from the Pubmed database between 1990 and 2018. The MeshTerm "benign prostatic hyperplasia", "epidemiology", "prevalence", and "incidence" were used to identify key articles of interest. These references were analyzed on the basis of the titles and summaries and cross-referenced with the cited references. The main articles selected were discussed by the authors before being summarized in this work. Results. - The relationship between BPH, LUTS, OSV and increased prostate volume is difficult to establish. In the context of epidemiological studies, these difficulties have a major impact on the accuracy of the results that are proposed. Nevertheless, we see that global demographics and increased life expectancy are leading to a steady increase in the prevalence of this disease. The corresponding health expenditure is also increasing, but more rapidly, posing major public health issues. The analysis of national health system databases confirms the steady and significant increase in the number of patients medically treated while the number of operated patients remains stable for several years. Conclusion. - The number of patients treated for BPH-related LUTS is steadily increasing. The related health expenditures increase exponentially while their efficiency remains poorly assessed from a medico-economic point of view. Given the frequency of this pathology and the resulting financial stakes, improving the quality of life and preventing complications must remain the main objectives of the medical care offered to patients. (C) 2018 Published by Elsevier Masson SAS.
引用
收藏
页码:803 / 812
页数:10
相关论文
共 50 条
  • [21] Options for the Treatment of Benign Prostatic Hyperplasia
    Plante, Mark
    Wachterman, Jared
    Perrapato, Scott
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2012, 22 (04): : 281 - 287
  • [22] Interventional treatment of benign prostatic hyperplasia
    Rauch, M.
    Strunk, H.
    RADIOLOGE, 2017, 57 (08): : 652 - 658
  • [23] Comparison of Clinical and Physiological Parameters for Benign Prostatic Hyperplasia in Hypertensive and Normotensive Patients
    Zeng, Xian-Tao
    Wang, Hong
    Xiong, Jing
    Huang, Qiao
    Ma, Lin-Lu
    Jin, Ying-Hui
    Wang, Xing-Huan
    FRONTIERS IN PHYSIOLOGY, 2018, 9
  • [24] Antegrade ejaculation preservation in surgical treatment for benign prostatic hyperplasia: quest for balance between voiding and sexual function
    Lopategui, Diana M.
    Shah, Hemendra N.
    Herrmann, Thomas R. W.
    CURRENT OPINION IN UROLOGY, 2024, 34 (04) : 286 - 293
  • [25] Nationwide incidence and treatment pattern of benign prostatic hyperplasia in Korea
    Lee, Young Ju
    Lee, Jeong Woo
    Park, Juhyun
    Seo, Seong Il
    Chung, Jae Il
    Yoo, Tag Keun
    Son, Hwancheol
    INVESTIGATIVE AND CLINICAL UROLOGY, 2016, 57 (06) : 424 - 430
  • [26] Finasteride Reduces the Risk of Incident Clinical Benign Prostatic Hyperplasia
    Parsons, J. Kellogg
    Schenk, Jeannette M.
    Arnold, Kathryn B.
    Messer, Karen
    Till, Cathee
    Thompson, Ian M.
    Kristal, Alan R.
    EUROPEAN UROLOGY, 2012, 62 (02) : 234 - 241
  • [27] Natural history and epidemiology of benign prostatic hyperplasia
    Lu, Shing-Hwa
    Chen, Chih-Shou
    FORMOSAN JOURNAL OF SURGERY, 2014, 47 (06) : 207 - 210
  • [28] Management of Benign Prostatic Hyperplasia
    Kim, Eric H.
    Larson, Jeffrey A.
    Andriole, Gerald L.
    ANNUAL REVIEW OF MEDICINE, VOL 67, 2016, 67 : 137 - 151
  • [29] Silodosin for Benign Prostatic Hyperplasia
    Cantrell, Matthew A.
    Bream-Rouwenhorst, Heather R.
    Hemerson, Phyllis
    Magera, James S., Jr.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (02) : 302 - 310
  • [30] Pharmacotherapy and herbal treatment of benign prostatic hyperplasia
    Sun, Jianming
    Zhang, Xiaoping
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2014, 19 : 789 - 797